Latest in Healthcare

Are Wall Street Analysts Predicting Pfizer’s Stock Will Climb or Sink?

Cerebras Fell After Culper Research Issued a Short Call. What This Means for CBRS Stock.

AbbVie Non-GAAP EPS of $3.82 beats by $0.05, revenue of $17.4B beats by $50M, raises FY guidance

AbbVie Non-GAAP EPS of $3.82 beats by $0.05, revenue of $17.4B beats by $50M, raises FY guid - AbbVie press release (ABBV): Q3 Non-GAAP EPS of $3.82 beats by $0.05. - Revenue of $17.4B (+10.3% Y/Y) beats by $50M. - Third-Quarter Global Net Revenues from the Immunology Portfolio Were $9.165 Billion, an Increase of…

NRx Pharma rises on FDA nod for generic ketamine injection

NRx Pharmaceuticals (NRXP) stock gains as the FDA approves its generic ketamine injection, potentially easing supply constraints for therapy. Read more here. - NRx Pharmaceuticals (NRXP) added more than 15% in premarket trading on Friday after the FDA approved its generic ketamine…

Bambusa Therapeutics prices upsized IPO at $16 per share

Bambusa Therapeutics (BBTX) priced its upsized initial public offering at $16 per share, offering 10.56M common shares. The company expects to raise ~$168.9M in gross proceeds before offering expenses. Underwriters have been granted a 30-day option to purchase up to an additional 1.58M shares…

AbbVie lifts profit forecast as immunology drugs continue to fuel growth

Oct 30 (Reuters) – AbbVie raised its annual profit forecast after topping Wall Street expectations for the third quarter on Friday, as booming sales of newer immunology drugs ​made up for the decline in former top-selling treatment ‌Humira. AbbVie’s immunology franchise, led…

Gilead Sciences: Why I Remain Bullish After Q3

Gilead Sciences had a strong Q3, while successfully shifting its R&D focus from HIV to the immunology market. Read why GILD stock is a buy. - Sales of Trodelvy, a Trop-2-directed antibody-drug conjugate approved for the treatment of breast cancer,…

Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow

Takeda Pharmaceutical is reiterated as a hold, with concerns about its ability to replace major drug revenues and current valuation. Read more on TAK stock here. - Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace…

Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid First

Nanobiotix stock hinges on J&J’s JNJ-1900 Phase 3 success, with delayed catalysts and lender claims pressuring upside. Click here to read more on NBTX. - Nanobiotix S.A. is now primarily dependent on J&J's development and commercialization of its lead asset,…

AbbVie Reports Third-Quarter 2026 Financial Results

NORTH CHICAGO, Ill., Oct. 30, 2026 /PRNewswire/ -- AbbVie announced financial results for the third quarter ended September 30, 2026. Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. Company Declares Dividend…